Abstract #0088
A T2* MRI Prospective Survey on Pancreatic Iron in Thalassemia Major Patients Treated with Deferasirox, Deferiprone and Desferrioxamine
Antonella Meloni 1 , Gennaro Restaino 2 , Stefania Renne 3 , Massimiliano Missere 2 , Maria Chiara Resta 4 , Vincenzo Positano 1 , Daniele De Marchi 1 , Gaetano Roccamo 5 , Nicola Romano 6 , Maria Giovanna Neri 1 , and Alessia Pepe 1
1
CMR Unit, Fondazione G. Monasterio
CNR-Regione Toscana, Pisa, Italy,
2
Dipartimento
di Radiologia, Universit Cattolica del Sacro Cuore,
Campobasso, Italy,
3
Struttura
Complessa di Cardioradiologia-UTIC, P.O. Giovanni Paolo
II, Lamezia Terme, Italy,
4
Struttura
Complessa di Radiologia, OSP. SS. Annunziata ASL
Taranto, Taranto, Italy,
5
Unit
di Prevenzione e Cura delle Mictrocitemie, PO di S.
Agata di Militello (ASP-ME), S. Agata di Militello (ME),
Italy,
6
S.C.
Medicina Trasfusionale, AO Arcispedale "S. Maria Nuova",
Reggio Emilia, Italy
For the first time, we described the changes in
pancreatic T2* values over a follow-up (FU) of 18 months
and we evaluated prospectively the effectiveness of the
three iron chelators in monotherapy in thalassemia major
(TM) patients. At the dosages used in the clinical
practice all three chelators in monotherapy allowed a
significant reduction in pancreatic iron.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
